| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(11)60204-3 |
| P698 | PubMed publication ID | 21492926 |
| P50 | author | Zegabriel Tedla | Q57890252 |
| Peter H. Kilmarx | Q40133323 | ||
| P2093 | author name string | Nong Shang | |
| Kenneth G Castro | |||
| Elizabeth A Talbot | |||
| Lorna Bozeman | |||
| Charles D Wells | |||
| Taraz Samandari | |||
| Barudi Mosimaneotsile | |||
| Margarett K Davis | |||
| Howard J Moffat | |||
| Samba Nyirenda | |||
| Thabisa Sibanda | |||
| Themba L Moeti | |||
| Tefera B Agizew | |||
| Oaitse I Motsamai | |||
| P2860 | cites work | Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study | Q46778392 |
| Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection | Q72225808 | ||
| Preventing latent tuberculosis among HIV-infected patients: efficacious and effective, yet inefficient? | Q79402182 | ||
| Treatment of latent tuberculosis infection in HIV infected persons | Q24241052 | ||
| Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001 | Q28469286 | ||
| Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults | Q32054823 | ||
| Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials | Q33832950 | ||
| Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients | Q33971595 | ||
| Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia | Q34064629 | ||
| The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil | Q34717877 | ||
| Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort | Q34717889 | ||
| IL-10-producing T cells suppress immune responses in anergic tuberculosis patients | Q35159232 | ||
| Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration | Q36548072 | ||
| Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme | Q37047696 | ||
| Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa | Q37240761 | ||
| High rates of clustering of strains causing tuberculosis in Harare, Zimbabwe: a molecular epidemiological study | Q37576902 | ||
| Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda | Q38878250 | ||
| Cytokine responses and progression to active tuberculosis in HIV-1-infected Ugandans: a prospective study | Q38881717 | ||
| Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults | Q38884867 | ||
| A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration | Q38887663 | ||
| Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya | Q39023628 | ||
| The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi | Q39025474 | ||
| Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control | Q39163402 | ||
| Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis | Q39713565 | ||
| Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana | Q40797865 | ||
| Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana | Q40798969 | ||
| Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana | Q40800733 | ||
| Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He | Q42622399 | ||
| Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy | Q44479756 | ||
| Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy | Q45734056 | ||
| A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. | Q45761546 | ||
| Twice weekly tuberculosis preventive therapy in HIV infection in Zambia | Q46730612 | ||
| P433 | issue | 9777 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Botswana | Q963 |
| tuberculosis | Q12204 | ||
| HIV | Q15787 | ||
| placebo | Q269829 | ||
| isoniazid | Q423169 | ||
| P304 | page(s) | 1588-1598 | |
| P577 | publication date | 2011-04-12 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial | |
| P478 | volume | 377 |
| Q28547313 | A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study |
| Q35766814 | A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study |
| Q34533997 | A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town |
| Q37702101 | Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings |
| Q33759993 | Added value of QuantiFERON TB-gold in-tube for detecting latent tuberculosis infection among persons living with HIV/AIDS. |
| Q54222775 | Addressing knowledge gaps and prevention for tuberculosis-infected Indian adults: a vital part of elimination. |
| Q40063284 | Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study |
| Q36106589 | Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis |
| Q34387168 | Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis |
| Q42233906 | Aspiring to zero tuberculosis deaths among southern Africa's miners: is there a way forward? |
| Q38619860 | Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation |
| Q38805328 | Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic |
| Q92572142 | Building a tuberculosis-free world: The Lancet Commission on tuberculosis |
| Q47094082 | CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis. |
| Q44032418 | Cancer in Botswana: resources and opportunities |
| Q37322344 | Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography |
| Q33596103 | Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests |
| Q37021617 | Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis |
| Q35800557 | Comparison of screening strategies to improve the diagnosis of latent tuberculosis infection in the HIV-positive population: a cohort study |
| Q33768889 | Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012 |
| Q54916195 | Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. |
| Q41284385 | Complicated silicotuberculosis in a South African gold miner: A case report |
| Q38686803 | Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. |
| Q64098100 | Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB |
| Q28087385 | Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection |
| Q35577840 | Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations |
| Q34672436 | Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil |
| Q37192288 | Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India |
| Q36950190 | Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. |
| Q33746657 | Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study |
| Q38066198 | Current management options for latent tuberculosis: a review |
| Q28069032 | Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis |
| Q27015848 | Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list' |
| Q35567798 | Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons |
| Q26991633 | Diagnosis & treatment of tuberculosis in HIV co-infected patients |
| Q37960565 | Diagnosis and management of TB in children: an update |
| Q27021614 | Diagnosis and treatment of latent infection with Mycobacterium tuberculosis |
| Q34290177 | Diagnosis and treatment of latent tuberculosis infection: an update |
| Q39037330 | Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland |
| Q85024214 | Duration of isoniazid preventive therapy in HIV-infected patients |
| Q95396469 | Duration of isoniazid preventive therapy in HIV-infected patients |
| Q37507184 | Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial |
| Q35818084 | Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. |
| Q47615033 | Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial |
| Q35744636 | Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study. |
| Q30240445 | Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review |
| Q48171817 | Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist |
| Q34515554 | Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial |
| Q37061089 | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial |
| Q41009954 | Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis |
| Q30385352 | Getting to 90-90-90 in paediatric HIV: What is needed? |
| Q89695446 | Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 |
| Q26824501 | HIV and tuberculosis--science and implementation to turn the tide and reduce deaths |
| Q39002151 | HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies |
| Q64243730 | Health system barriers to implementation of TB preventive strategies in South African primary care facilities |
| Q27022370 | Hepatotoxicity from antituberculous therapy in the elderly: a systematic review |
| Q26824057 | How can mathematical models advance tuberculosis control in high HIV prevalence settings? |
| Q37103666 | Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment |
| Q40600140 | IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis |
| Q34639121 | Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model |
| Q33886920 | Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. |
| Q37461125 | Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana |
| Q38957843 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy |
| Q38841837 | Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. |
| Q35357639 | Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research |
| Q90683207 | Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study |
| Q92598911 | Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India |
| Q40794905 | Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey |
| Q92858776 | Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children |
| Q90669515 | Intensified household contact tracing, prevention and treatment support versus enhanced standard of care for contacts of tuberculosis cases in South Africa: study protocol for a household cluster-randomised trial |
| Q36599355 | Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. |
| Q36637982 | Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence |
| Q38168914 | Interferon-gamma release assays for tuberculosis: current and future applications |
| Q40522525 | Is systematic screening and treatment for latent tuberculosis infection in HIV patients useful in a low endemic setting? |
| Q46171041 | Isoniazid Preventive Therapy for People with HIV who are Heavy Alcohol Drinkers in High TB/HIV Burden Countries: a Risk-Benefit Analysis |
| Q90438291 | Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women |
| Q26778385 | Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials |
| Q34519039 | Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial |
| Q57827499 | Isoniazid preventive therapy in HIV infection |
| Q42245812 | Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards |
| Q35197248 | Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study |
| Q34467936 | Longer hospital stay is associated with higher rates of tuberculosis-related morbidity and mortality within 12 months after discharge in a referral hospital in Sub-Saharan Africa |
| Q38107500 | Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons |
| Q38259519 | Meningitis in HIV-positive patients in sub-Saharan Africa: a review |
| Q36171368 | Molecular epidemiology of HIV-associated tuberculosis in Dar es Salaam, Tanzania: strain predominance, clustering, and polyclonal disease |
| Q58592157 | Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection |
| Q37061276 | Mycobacterial Etiology of Pulmonary Tuberculosis and Association with HIV Infection and Multidrug Resistance in Northern Nigeria |
| Q36125227 | New regimens to prevent tuberculosis in adults with HIV infection |
| Q35947091 | Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection |
| Q40696371 | Poor agreement between diagnostic tests for latent tuberculosis infection among HIV-infected persons in Hong Kong |
| Q34999621 | Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis |
| Q27000984 | Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis |
| Q34648833 | Predictors of tuberculosis and human immunodeficiency virus co-infection: a case-control study |
| Q36711601 | Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy |
| Q34589601 | Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa |
| Q54215180 | Preventive treatment for tuberculosis in people with HIV. |
| Q37626250 | Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database |
| Q57460874 | Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting |
| Q92365471 | Provider barriers to the uptake of isoniazid preventive therapy among people living with HIV in Ethiopia |
| Q37520181 | Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy |
| Q38797602 | Reactivation tuberculosis: role of surveillance |
| Q37940571 | Redefining latent tuberculosis |
| Q37285167 | Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa |
| Q47145955 | Rheumatic heart disease: infectious disease origin, chronic care approach. |
| Q24201325 | Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB |
| Q41657767 | Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. |
| Q36154640 | Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment |
| Q33889133 | Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana |
| Q33768706 | Risk factors for treatment default in close contacts with latent tuberculous infection |
| Q35566421 | Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test |
| Q38819485 | Scale-up of collaborative TB/HIV activities in Guyana |
| Q38011369 | Scaling up interventions to achieve global tuberculosis control: progress and new developments |
| Q61815841 | Scaling up isoniazid preventive therapy in Zimbabwe: has operational research influenced policy and practice? |
| Q38783382 | Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings. |
| Q42923385 | Short-course untargeted isoniazid preventive therapy in South Africa: time to rethink policy? |
| Q35547966 | Statistical inference methods for two crossing survival curves: a comparison of methods |
| Q28478920 | Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis |
| Q34499835 | Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy |
| Q33805502 | Systematic review of facility-based sexual and reproductive health services for female sex workers in Africa |
| Q59359915 | TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings |
| Q46706694 | Taking the long view on the CREATE studies' findings |
| Q37284765 | Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service |
| Q53727381 | The ENRICH Study to evaluate the effectiveness of a combination intervention package to improve isoniazid preventive therapy initiation, adherence and completion among people living with HIV in Ethiopia: rationale and design of a mixed methods clust |
| Q38863238 | The HIV basic care package: where is it available and who receives it? Findings from a mixed methods evaluation in Kenya and Uganda |
| Q91790814 | The Mtb-HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1 eradication |
| Q42279763 | The Twin Epidemics of Tuberculosis and HIV. |
| Q40095857 | The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study |
| Q28483035 | The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis |
| Q35382545 | The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study |
| Q47159987 | The effect of micronutrient supplementation on active TB incidence early in HIV infection in Botswana |
| Q51833634 | The molecular epidemiology of tuberculosis in settings with a high HIV prevalence: implications for control. |
| Q34251459 | The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals |
| Q34802722 | The proportions of people living with HIV in low and middle-income countries who test tuberculin skin test positive using either a 5 mm or a 10 mm cut-off: a systematic review |
| Q30385976 | The rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy. |
| Q64079571 | The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi |
| Q36720436 | The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study |
| Q38729690 | The transmission of Mycobacterium tuberculosis in high burden settings |
| Q37525288 | Timely HIV diagnosis and HIV/TB comanagement among California patients in 2008. |
| Q47955589 | To eliminate tuberculosis, we must universally encourage treatment of its latent form |
| Q62487117 | Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study |
| Q36137225 | Treatment of latent tuberculosis infection in HIV: shorter or longer? |
| Q55440266 | Tuberculin Skin Test Conversion among Individuals with Human Immunodeficiency Virus Infection on Antiretroviral Therapy in a Referral Teaching Hospital, Tehran, Iran. |
| Q57235679 | Tuberculosis |
| Q59200569 | Tuberculosis |
| Q35297467 | Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy |
| Q64357339 | Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region |
| Q45998638 | Tuberculosis in HIV-infected persons in British Columbia during the HAART era. |
| Q37461120 | Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis |
| Q36078532 | Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy |
| Q34222186 | Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community |
| Q35304473 | Tuberculosis prevention in South Africa |
| Q58580044 | Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India |
| Q51120505 | Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience. |
| Q26774267 | Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children |
| Q53669745 | Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. |
| Q36238015 | Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies |
| Q28073158 | Updates on the risk factors for latent tuberculosis reactivation and their managements |
| Q38376719 | Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature |
| Q46361434 | Venous thromboembolism prophylaxis, shorter courses of isoniazid for tuberculosis, and the microbiome in asthma |
| Q28066845 | What can we offer to 3 million MDRTB household contacts in 2016? |
| Q36044825 | Wide Variations in Compliance with Tuberculosis Screening Guidelines and Tuberculosis Incidence between Antiretroviral Therapy Facilities - Côte d'Ivoire |
| Q33790711 | Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging |
| Q26753069 | Year in review 2015: Lung cancer, pleural diseases, respiratory infections, bronchiectasis and tuberculosis, bronchoscopic intervention and imaging |
| Q28817658 | [Au]/[Ag]-catalysed expedient synthesis of branched heneicosafuranosyl arabinogalactan motif of Mycobacterium tuberculosis cell wall |
| Q84590878 | [Clinical presentation of tuberculosis in routine practice] |
Search more.